Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Study Number
3330822
Phase
I
Age Group
Adult
Principal Investigator
Matthew Cortese
Purpose

This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.

Check your eligibility for this trial
Check now
Full Title

A Phase 1 Study to Evaluate the Safety and Tolerability of a 2-component autologous CD19 CAR T cell therapy (STK-009 and SYNCAR-001) in Subjects with Relapsed or Refractory CD19+ Hematologic Malignancies.

ClinicalTrials.Gov ID
NCT05665062

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.